Literature DB >> 33608263

Recurrent Hyperkalemia in Renin-Angiotensin-Aldosterone System Inhibitor (RAASi) Treatment: Stuck between a Rock and a Hard Place.

Jonathan A Bolaños1, Stephen L Seliger1.   

Abstract

Entities:  

Keywords:  cardiovascular disease; hyperkalemia; renin angiotensin system

Mesh：

Substances：

Year:  2021        PMID： 33608263      PMCID： PMC8011015          DOI： 10.2215/CJN.00950121

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN： 1555-9041            Impact factor:   8.237


× No keyword cloud information.
  9 in total

Review 1.  Hyperkalemia in patients with chronic renal failure.

Authors:  Stephen L Seliger
Journal:  Nephrol Dial Transplant       Date:  2019-12-01       Impact factor: 5.992

2.  Risk of hyperkalemia in nondiabetic patients with chronic kidney disease receiving antihypertensive therapy.

Authors:  Joy M Weinberg; Lawrence J Appel; George Bakris; Jennifer J Gassman; Tom Greene; Cynthia A Kendrick; Xuelei Wang; James Lash; Julia A Lewis; Velvie Pogue; Denyse Thornley-Brown; Robert A Phillips
Journal:  Arch Intern Med       Date:  2009-09-28

3.  Antihypertensive Medications and the Prevalence of Hyperkalemia in a Large Health System.

Authors:  Alex R Chang; Yingying Sang; Julia Leddy; Taher Yahya; H Lester Kirchner; Lesley A Inker; Kunihiro Matsushita; Shoshana H Ballew; Josef Coresh; Morgan E Grams
Journal:  Hypertension       Date:  2016-04-11       Impact factor: 10.190

4.  Association Between Renin-Angiotensin System Blockade Discontinuation and All-Cause Mortality Among Persons With Low Estimated Glomerular Filtration Rate.

Authors:  Yao Qiao; Jung-Im Shin; Teresa K Chen; Lesley A Inker; Josef Coresh; G Caleb Alexander; John W Jackson; Alex R Chang; Morgan E Grams
Journal:  JAMA Intern Med       Date:  2020-05-01       Impact factor: 21.873

5.  The frequency of hyperkalemia and its significance in chronic kidney disease.

Authors:  Lisa M Einhorn; Min Zhan; Van Doren Hsu; Lori D Walker; Maureen F Moen; Stephen L Seliger; Matthew R Weir; Jeffrey C Fink
Journal:  Arch Intern Med       Date:  2009-06-22

Review 6.  Use of Renin-Angiotensin System Blockade in Advanced CKD: An NKF-KDOQI Controversies Report.

Authors:  Matthew R Weir; Jay I Lakkis; Bernard Jaar; Michael V Rocco; Michael J Choi; Holly J Kramer; Elaine Ku
Journal:  Am J Kidney Dis       Date:  2018-09-07       Impact factor: 8.860

7.  Ambulatory Treatments for RAAS Inhibitor-Related Hyperkalemia and the 1-Year Risk of Recurrence.

Authors:  Gregory L Hundemer; Robert Talarico; Navdeep Tangri; Silvia J Leon; Sarah E Bota; Emily Rhodes; Greg A Knoll; Manish M Sood
Journal:  Clin J Am Soc Nephrol       Date:  2021-02-19       Impact factor: 8.237

8.  Stopping Renin-Angiotensin System Inhibitors in Patients with Advanced CKD and Risk of Adverse Outcomes: A Nationwide Study.

Authors:  Edouard L Fu; Marie Evans; Catherine M Clase; Laurie A Tomlinson; Merel van Diepen; Friedo W Dekker; Juan J Carrero
Journal:  J Am Soc Nephrol       Date:  2020-12-28       Impact factor: 10.121

9.  Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEi trial.

Authors:  Sunil Bhandari; Natalie Ives; Elizabeth A Brettell; Marie Valente; Paul Cockwell; Peter S Topham; John G Cleland; Arif Khwaja; Meguid El Nahas
Journal:  Nephrol Dial Transplant       Date:  2015-09-30       Impact factor: 5.992
  9 in total
  1 in total

1.  The Cost Effectiveness of Patiromer for the Treatment of Hyperkalaemia in Patients with Chronic Kidney Disease with and without Heart Failure in Ireland.

Authors:  Thomas Ward; Tray Brown; Ruth D Lewis; Melodi Kosaner Kliess; Antonio Ramirez de Arellano; Carol M Quinn
Journal:  Pharmacoecon Open       Date:  2022-08-04
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.